NDAQ:FDMT) 4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path ...

Glooko Inc. and Hedia ApS launched an integrated software solution in the U.K. to support people with diabetes who require advanced doses of bolus insulin. The solution combines Glooko’s diabetes ...

"CeQur raises $120m to advance wearable insulin patch commercialisation" was originally created and published by Medical Device Network, a GlobalData owned brand.

Glooko and Hedia launched their interoperable solution, combining connected care, remote patient monitoring, and digital therapeutics for diabetes.

2 For people with diabetes who do not have an insulin pump, calculating the appropriate bolus dose can present a challenge for them and their physicians. With the Glooko platform, patients can ...

Table 1. Comparisons between the two control groups in the two studies Gary J. Browne, FRACP, FACEM, Lawrence T. Lam, MApp, PsyMPH, Emergency Department, Children's Hospital at Westmead, Royal ...

These outcomes indicated that the intrathecally administered therapy was well-tolerated at all dose levels, with only mild adverse events reported. Leveraging the company’s Smart Chemistry Aided ...